{"id":22045,"date":"2017-12-12T10:11:05","date_gmt":"2017-12-12T15:11:05","guid":{"rendered":"https:\/\/ipo.org\/?p=22045"},"modified":"2017-12-28T10:21:55","modified_gmt":"2017-12-28T15:21:55","slug":"written-description","status":"publish","type":"post","link":"https:\/\/ipo.org\/index.php\/written-description\/","title":{"rendered":"Written Description in the Life Sciences after <i> Amgen v. Sanofi <\/i>"},"content":{"rendered":"<p>Hatch-Waxman litigation with generic manufacturers has long been the focus of competition involving traditional small molecule drugs.\u00a0 The litigation between Amgen and Sanofi regarding large molecule next-generation cholesterol drugs, however, illustrates the new prominence of innovator vs. innovator litigation in the pharmaceutical industry.\u00a0 In these types of cases, the law of written description looms large because innovators might try to cover all possible drugs that focus on a biologic target while disclosing only a few examples of a possibly large genus.<\/p>\n<p>The recent Federal Circuit opinion in\u00a0<i>Amgen v. Sanofi,\u00a0<\/i>reversing Amgen\u2019s district court win, will have a significant impact from R&amp;D labs to court rooms.\u00a0 The Federal Circuit vacated a district court&#8217;s finding that Amgen&#8217;s claims for a genus of monoclonal antibodies were not invalid and a permanent injunction enjoining sales of Sanofi&#8217;s Praluent\u00ae- and remanded for a new trial.<\/p>\n<p>The Federal Circuit also made new law that will influence pharma litigation outside of antibodies. The district court had excluded evidence about Sanofi and co-defendant Regeneron\u2019s own products. The district court excluded the post-priority evidence because it \u201cdid not illuminate the state of the art at the time of filing.\u201d The Federal Circuit, by contrast, explained that evidence showing that species disclosed in a patent are not representative of a claimed genus is in fact likely to postdate the priority date, and is able to prove inadequate written description.<\/p>\n<p>Our panel includes the biotech counsel of a multinational innovator company, and two top litigators. They will discuss:<\/p>\n<ul type=\"disc\">\n<li>What is now needed by way of written description to create a valid patent on an antibody? The entire DNA sequence? Just the CDRs? The entire 3D structure?<\/li>\n<li>How does\u00a0<i>Amgen v. Sanofi<\/i>\u00a0clarify the law beyond earlier cases such as\u00a0<i>Abbvie v. Janssen\u00a0<\/i>and\u00a0<i>Ariad v. Lilly?<\/i><\/li>\n<\/ul>\n<p>How will pharma litigation change after the case, and how will it affect specific pending cases including challenges on Amgen\u2019s Embrel\u00ae?<\/p>\n<p>Speakers:<\/p>\n<ul type=\"disc\">\n<li>Jane Love,\u00a0<i>Gibson, Dunn &amp; Crutcher LLP<\/i><\/li>\n<li>Duane Marks,\u00a0<i>Eli, Lilly &amp; Company<\/i><\/li>\n<li>Irena Royzman,\u00a0<i>Patterson Belknap Webb &amp; Tyler LLP<\/i><\/li>\n<\/ul>\n","protected":false},"excerpt":{"rendered":"<p>Hatch-Waxman litigation with generic manufacturers has long been the focus  [&#8230;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[1],"tags":[],"class_list":["post-22045","post","type-post","status-publish","format-standard","hentry","category-uncategorized"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Written Description in the Life Sciences after  Amgen v. Sanofi  - Intellectual Property Owners Association<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ipo.org\/index.php\/written-description\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Written Description in the Life Sciences after  Amgen v. Sanofi  - Intellectual Property Owners Association\" \/>\n<meta property=\"og:description\" content=\"Hatch-Waxman litigation with generic manufacturers has long been the focus [...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ipo.org\/index.php\/written-description\/\" \/>\n<meta property=\"og:site_name\" content=\"Intellectual Property Owners Association\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/IPOAssociation\/\" \/>\n<meta property=\"article:published_time\" content=\"2017-12-12T15:11:05+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2017-12-28T15:21:55+00:00\" \/>\n<meta name=\"author\" content=\"ipoadmin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@ipo\" \/>\n<meta name=\"twitter:site\" content=\"@ipo\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"ipoadmin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/ipo.org\\\/index.php\\\/written-description\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/ipo.org\\\/index.php\\\/written-description\\\/\"},\"author\":{\"name\":\"ipoadmin\",\"@id\":\"https:\\\/\\\/ipo.org\\\/#\\\/schema\\\/person\\\/8226b50acbf234bbf0f5d70f4a84ba47\"},\"headline\":\"Written Description in the Life Sciences after Amgen v. Sanofi\",\"datePublished\":\"2017-12-12T15:11:05+00:00\",\"dateModified\":\"2017-12-28T15:21:55+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/ipo.org\\\/index.php\\\/written-description\\\/\"},\"wordCount\":355,\"publisher\":{\"@id\":\"https:\\\/\\\/ipo.org\\\/#organization\"},\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/ipo.org\\\/index.php\\\/written-description\\\/\",\"url\":\"https:\\\/\\\/ipo.org\\\/index.php\\\/written-description\\\/\",\"name\":\"Written Description in the Life Sciences after Amgen v. Sanofi - Intellectual Property Owners Association\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/ipo.org\\\/#website\"},\"datePublished\":\"2017-12-12T15:11:05+00:00\",\"dateModified\":\"2017-12-28T15:21:55+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/ipo.org\\\/index.php\\\/written-description\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/ipo.org\\\/index.php\\\/written-description\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/ipo.org\\\/index.php\\\/written-description\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/ipo.org\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Written Description in the Life Sciences after Amgen v. Sanofi\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/ipo.org\\\/#website\",\"url\":\"https:\\\/\\\/ipo.org\\\/\",\"name\":\"Intellectual Property Owners Association\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/ipo.org\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/ipo.org\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/ipo.org\\\/#organization\",\"name\":\"Intellectual Property Owners Association\",\"url\":\"https:\\\/\\\/ipo.org\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/ipo.org\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/ipo.org\\\/wp-content\\\/uploads\\\/2019\\\/06\\\/ipo_logo.png\",\"contentUrl\":\"https:\\\/\\\/ipo.org\\\/wp-content\\\/uploads\\\/2019\\\/06\\\/ipo_logo.png\",\"width\":570,\"height\":226,\"caption\":\"Intellectual Property Owners Association\"},\"image\":{\"@id\":\"https:\\\/\\\/ipo.org\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/IPOAssociation\\\/\",\"https:\\\/\\\/x.com\\\/ipo\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/ipoassociation\\\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/ipo.org\\\/#\\\/schema\\\/person\\\/8226b50acbf234bbf0f5d70f4a84ba47\",\"name\":\"ipoadmin\",\"url\":\"https:\\\/\\\/ipo.org\\\/index.php\\\/author\\\/ipoadmin\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Written Description in the Life Sciences after  Amgen v. Sanofi  - Intellectual Property Owners Association","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ipo.org\/index.php\/written-description\/","og_locale":"en_US","og_type":"article","og_title":"Written Description in the Life Sciences after  Amgen v. Sanofi  - Intellectual Property Owners Association","og_description":"Hatch-Waxman litigation with generic manufacturers has long been the focus [...]","og_url":"https:\/\/ipo.org\/index.php\/written-description\/","og_site_name":"Intellectual Property Owners Association","article_publisher":"https:\/\/www.facebook.com\/IPOAssociation\/","article_published_time":"2017-12-12T15:11:05+00:00","article_modified_time":"2017-12-28T15:21:55+00:00","author":"ipoadmin","twitter_card":"summary_large_image","twitter_creator":"@ipo","twitter_site":"@ipo","twitter_misc":{"Written by":"ipoadmin","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/ipo.org\/index.php\/written-description\/#article","isPartOf":{"@id":"https:\/\/ipo.org\/index.php\/written-description\/"},"author":{"name":"ipoadmin","@id":"https:\/\/ipo.org\/#\/schema\/person\/8226b50acbf234bbf0f5d70f4a84ba47"},"headline":"Written Description in the Life Sciences after Amgen v. Sanofi","datePublished":"2017-12-12T15:11:05+00:00","dateModified":"2017-12-28T15:21:55+00:00","mainEntityOfPage":{"@id":"https:\/\/ipo.org\/index.php\/written-description\/"},"wordCount":355,"publisher":{"@id":"https:\/\/ipo.org\/#organization"},"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/ipo.org\/index.php\/written-description\/","url":"https:\/\/ipo.org\/index.php\/written-description\/","name":"Written Description in the Life Sciences after Amgen v. Sanofi - Intellectual Property Owners Association","isPartOf":{"@id":"https:\/\/ipo.org\/#website"},"datePublished":"2017-12-12T15:11:05+00:00","dateModified":"2017-12-28T15:21:55+00:00","breadcrumb":{"@id":"https:\/\/ipo.org\/index.php\/written-description\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ipo.org\/index.php\/written-description\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/ipo.org\/index.php\/written-description\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/ipo.org\/"},{"@type":"ListItem","position":2,"name":"Written Description in the Life Sciences after Amgen v. Sanofi"}]},{"@type":"WebSite","@id":"https:\/\/ipo.org\/#website","url":"https:\/\/ipo.org\/","name":"Intellectual Property Owners Association","description":"","publisher":{"@id":"https:\/\/ipo.org\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/ipo.org\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/ipo.org\/#organization","name":"Intellectual Property Owners Association","url":"https:\/\/ipo.org\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/ipo.org\/#\/schema\/logo\/image\/","url":"https:\/\/ipo.org\/wp-content\/uploads\/2019\/06\/ipo_logo.png","contentUrl":"https:\/\/ipo.org\/wp-content\/uploads\/2019\/06\/ipo_logo.png","width":570,"height":226,"caption":"Intellectual Property Owners Association"},"image":{"@id":"https:\/\/ipo.org\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/IPOAssociation\/","https:\/\/x.com\/ipo","https:\/\/www.linkedin.com\/company\/ipoassociation\/"]},{"@type":"Person","@id":"https:\/\/ipo.org\/#\/schema\/person\/8226b50acbf234bbf0f5d70f4a84ba47","name":"ipoadmin","url":"https:\/\/ipo.org\/index.php\/author\/ipoadmin\/"}]}},"_links":{"self":[{"href":"https:\/\/ipo.org\/index.php\/wp-json\/wp\/v2\/posts\/22045","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ipo.org\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ipo.org\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ipo.org\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/ipo.org\/index.php\/wp-json\/wp\/v2\/comments?post=22045"}],"version-history":[{"count":1,"href":"https:\/\/ipo.org\/index.php\/wp-json\/wp\/v2\/posts\/22045\/revisions"}],"predecessor-version":[{"id":22047,"href":"https:\/\/ipo.org\/index.php\/wp-json\/wp\/v2\/posts\/22045\/revisions\/22047"}],"wp:attachment":[{"href":"https:\/\/ipo.org\/index.php\/wp-json\/wp\/v2\/media?parent=22045"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ipo.org\/index.php\/wp-json\/wp\/v2\/categories?post=22045"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ipo.org\/index.php\/wp-json\/wp\/v2\/tags?post=22045"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}